Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib in ALK-positive solid tumors
NCT04644315Phase 2Terminated
- Sponsor
- Roche
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alectinib in solid tumor, sponsored by Roche. Primary endpoint: Confirmed Objective Response Rate at 1 year. Started May 2021; status: terminated.
02
Drugs
alectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04644315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644315.